Combined oral hormone replacement therapy formulations

American Journal of Obstetrics and Gynecology

Volumn 185, Issue 2 SUPPL., 2001, Pages

  Mattox, John H ^a   Shulman, Lee P ^b  

^a BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Activella; Bleeding; Endometrial protection; femhrt; Lipoproteins; ORTHO PREFEST; PREMPRO; Tolerability; Vasomotor symptoms

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; GESTAGEN; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; COLON CANCER; DRUG FORMULATION; DRUG TOLERABILITY; HORMONE SUBSTITUTION; MENOPAUSE; ORAL CONTRACEPTION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; VAGINA ATROPHY; VASOMOTOR REFLEX;

EID: 0034877435     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2001.117417     Document Type: Article

References (41)

1. Use of progestogen therapy
2. Estrogens and progestins
3. Current perspectives on the benefits of HRT in menopausal women
4. Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis
5. Hormone replacement therapy reverses the decrease in natural killer cytotoxicity but does not reverse the decreases in the T-cell subpopulation or interferon-gamma production in postmenopausal women
6. Synthetic sex steroids
7. Injectable contraception
8. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy
9. Symptom relief and side effects of postmenopausal hormones: Results from the Postmenopausal Estrogen/Progestin Interventions trial
10. Metabolic impact of adding medroxy-progesterone acetate to conjugated estrogen therapy in postmenopausal women
11. Comparative effect of norethindrone acetate (NA)/ethinyl estradiol (EE) (femhrt®) and 0.625 mg CEE/2.5 mg MPA (Prempro™) on bleeding control: Early results from a randomized, placebo-controlled trial
12. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study): A randomized controlled trial
13. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate
14. A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement
15. 17β-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy
16. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms?
17. Low doses of 17β-estradiol and norethisterone acetate as continuous combined replacement therapy in postmenopausal women: Lipid metabolic effects
18. The role and use of progestogens
19. Improving adherence to hormone replacement therapy with effective patient-physician communication
20. The symptomatology of progestogen intolerance
21. Progestogen addition during oestrogen replacement therapy - Effects on vasomotor symptoms and mood
22. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: A model for the premenstrual syndrome
23. Menopause
24. Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis
25. Continuation of postmenopausal hormone replacement therapy: Comparison of cyclic versus continuous combined schedules
26. Estrogen with interrupted progestin HRT: A review of experimental and clinical studies
27. Regulation of estrogen/progestogen receptors in the endometrium
28. Human endometrial cells in primary tissue culture: Modulation of the progesterone receptor level by natural and synthetic estrogens in vitro
29. Effect of a unique constant-estrogen, pulsed-progestin hormone replacement therapy containing 17β-estradiol and norgestimate on endometrial histology
30. Norgestimate
31. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy
32. Effects on serum lipid profiles of continuous 17β-estradiol, intermittent norgestimate regimens versus continuous combined 17β-estradiol/norethisterone acetate hormone replacement therapy
33. A novel intermittent regimen of norgestimate to preserve the beneficial effects of 17β-estradiol on lipid and lipoprotein profiles